Macquarie Group LTD Supernus Pharmaceuticals, Inc. Transaction History
Macquarie Group LTD
- $79.1 Billion
- Q2 2025
A detailed history of Macquarie Group LTD transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 2,762,124 shares of SUPN stock, worth $114 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
2,762,124
Previous 2,699,667
2.31%
Holding current value
$114 Million
Previous $88.4 Million
1.53%
% of portfolio
0.11%
Previous 0.11%
Shares
32 transactions
Others Institutions Holding SUPN
# of Institutions
312Shares Held
61.6MCall Options Held
11.4KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$429 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.21MShares$256 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.81MShares$198 Million2.66% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$125 Million0.02% of portfolio
-
State Street Corp Boston, MA2.21MShares$91.1 Million0.0% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.21B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...